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1. Introduction  
Prostate cancer is the most common malignancy and second leading cause of cancer related 
death in males in developed countries (Jemal et al. 2011). Patients with localized and 
metastatic prostate cancer are treated with anti-androgens. Although prostate cancer cell 
proliferation is initially blocked or slowed down with anti-androgen therapy, eventually 
castration-resistant disease develops (Sharifi, Gulley & Dahut 2010). Therapeutic options for 
castration-resistant prostate cancer are limited and treatment responses to currently existing 
therapies are often unsatisfactory (Bracarda et al. 2011). For example, the cytotoxic therapy 
often causes severe toxicity and eventually leads also to the development of chemo-
resistance (Tannock et al. 2004, Berthold et al. 2008, Bracarda et al. 2011). Thus, there is an 
urgent need for novel agents to block the proliferation and to inhibit the progression of the 
primary prostate cancer cells to the advanced stage as well as to target advanced and 
metastatic prostate cancer. Therefore, understanding of disease progression and drug 
resistance mechanisms may provide valuable insights into the development of novel 
treatment options to improve the survival of prostate cancer patients.  
We have recently performed a high-throughput cell-based screening of 4,910 known drugs 
and drug-like molecules in four prostate cancer cell models and two non-tumorigenic 
prostate epithelial cell lines to identify prostate cancer cell growth selective inhibitors (Iljin 
et al. 2009). Only four compounds, antibiotic ionophore monensin, aldehyde dehydrogenase 
(ALDH) inhibitor disulfiram, histone deacetylase inhibitor trichostatin A and fungicide 
thiram inhibited selectively cancer cell growth at nanomolar concentrations. The 
mechanistic studies indicated that monensin and disulfiram inhibited prostate cancer cell 
growth by inducing oxidative stress (Iljin et al. 2009, Ketola et al. 2010). In contrast to 
disulfiram, monensin induced apoptosis, reduced androgen receptor signalling and showed 
a synergistic anti-proliferative effect with anti-androgens in prostate cancer cells. Moreover, 
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monensin increased the amount of reactive oxygen species (ROS) and induced an oxidative 
stress signature in prostate cancer cells (VCaP and LNCaP), but not in the non-malignant 
prostate epithelial cells (RWPE-1, EP156T) (Ketola et al. 2010). Furthermore, antioxidant 
vitamin C partially rescued the monensin induced growth inhibition, indicating that 
oxidative stress plays a key role in the antineoplastic effect of monensin in cultured prostate 
cancer cells (Ketola et al. 2010).  
Oxidative stress occurs in the cell when redox regulation is imbalanced. Redox balance 
depends on the level of intracellular free radicals and reactive oxygen species as well as on 
the antioxidative capacity of the cell. Figure 1 illustrates the connection between the 
malignant progression and increase in intracellular ROS (Fig. 1).  
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Fig. 1. The balance between cell proliferation and intracellular reactive oxygen species 
(ROS). The malignant progression and the effects of ROS inducers and antioxidants depend 
on the intracellular levels of ROS. In cancer cells, intracellular ROS levels are higher than in 
normal cells making them more vulnerable to agents inducing ROS. Figure idea adapted 
from Gupte & Mumper 2009. 
Cancer cells benefit from the increased mutation rate induced via oxidative stress 
(Shibutani, Takeshita & Grollman 1991). Therefore, cancer cells need also an active 
antioxidative mechanism to be able to survive under high oxidative stress. The oxidative 
stress level is elevated in prostate cancer cells compared to non-malignant prostate epithelial 
cells (Khandrika et al. 2009, Yossepowitch et al. 2007, Kumar et al. 2008). Many oncogenes 
are known to protect cells from oxidative stress e.g. androgen receptor (AR), ERG and MYC 
are known to have antioxidative properties in cancer cells (Pinthus et al. 2007, Tam et al. 
2003, Benassi et al. 2006, Swanson et al. 2011, DeNicola et al. 2011). Monensin may sensitize 
prostate cancer cells to oxidative stress via reducing the expression of these genes (Ketola et 
al. 2010). In addition, many other anti-neoplastic agents such as vinblastine, cisplatin, 
mitomycin C, doxorubicin, camptothecin, inostamycin, neocarzinostatin, etoposide, arsenic 
trioxide and nonsteroidal anti-inflammatory drugs are known to mediate their apoptotic 
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effect by inducing oxidative stress (Fang, Nakamura & Iyer 2007, Rigas, Sun 2008, Sun et al. 
2011). The increased sensitivity to oxidative stress combined with dependency on anti-
oxidative system may provide a way to selectivity inhibit cancer cell proliferation (Iljin et al. 
2009, Ketola et al. 2010).  
Recently, redox control including antioxidative defence mechanisms and ROS-scavenging 
systems has been identified as an important regulator of cancer stem cell potential, 
metastasis and chemoresistance (Kobayashi, Suda 2011b, Cairns, Harris & Mak 2011, Pani, 
Galeotti & Chiarugi 2010). Aldehyde dehydrogenase activity is widely used as a marker for 
cancer stem cells and its activity has been shown to correlate with poor outcome in several 
cancers such as in prostate cancer (Davydov, Dobaeva & Bozhkov 2004, Burger et al. 2009, Li 
et al. 2010, Yu et al. 2011, Zhang et al. 2009a). Aldehyde dehydrogenases are detoxifying 
enzymes that are responsible for the oxidation of intracellular aldehydes (Duester 2000, 
Magni et al. 1996, Sophos, Vasiliou 2003, Yoshida et al. 1998). Moreover, ALDH oxidize 
retinol to retinoic acid (vitamin A) known to reduce oxidative stress whereas retinoic acid 
depletion induces oxidative stress and mitochondrial dysfunction (Ahlemeyer, Krieglstein 
1998, Ahlemeyer et al. 2001, Chiu, Fischman & Hammerling 2008, Duester 2000, Chute et al. 
2006). Thus, ALDH increases the antioxidative capacity in cells and protects cells from 
oxidative stress induction. Moreover, the inhibition of ALDH activity has recently been 
linked to reduced chemotherapy and radiation resistance in cancer stem cells (Croker, Allan 
2011). These results suggest that not only cancer cells, but also cancer stem cells could be 
targeted by oxidative stress induction and/or reduction of antioxidative capacity. 
Interestingly, the results from mechanistic studies of prostate cancer selective compounds 
indicated that both disulfiram and monensin reduced the ALDH activity in prostate cancer 
cells (Iljin et al. 2009, Ketola et al., 2010).  
In this study, we explored further the molecular mechanism of monensin induced growth 
inhibition in cultured prostate cancer cells. Cancer pathway reporter assays and steroid 
profiling was performed to get insights into altered signalling and metabolite levels in 
monensin exposed prostate cancer cells. Since monensin reduces ALDH activity, the 
putative effect on cancer stem cells was evaluated. Furthermore, we studied the effect of 
monensin on prostate cancer cell differentiation and motility.  
2. Materials and methods 
2.1 Cells 
VCaP prostate carcinoma cells (TMPRSS2-ERG positive, received from Drs. Adrie van 
Bokhoven, University of Colorado Health Sciences Center, Denver, Colorado and Kenneth 
Pienta, University of Michigan, Michigan) were grown in Dulbecco's Modified Eagle's 
Medium (Korenchuk et al. 2001b, Korenchuk et al. 2001a). LNCaP prostate carcinoma cells 
(received from Dr. Marco Cecchini, University of Bern, Bern, Switzerland) were grown in 
T-Medium (Invitrogen). PC-3 prostate carcinoma cells were purchased from American Type 
Culture Collection (LGC Promochem AB) and grown according to provider’s instructions. 
All cells were cultured in appropriate growth media described above including 10% fetal 
bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin 
in an incubator with a humidified atmosphere of 95% air and 5% CO2 at 37°C. 
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2.2 Compounds  
Monensin was purchased from Sigma-Aldrich and diluted in ethanol.  
2.3 Cancer 10-pathway reporter array 
Cancer 10-pathway Reporter Luciferase Kit (Wnt (TCF/LEF), Notch (RBP-Jκ), p53/DNA 
damage, TGF-β (SMAD2/3/4), Cell cycle/pRb-E2F (E2F/DP1), NF-κB, Myc/Max, Hypoxia 
(HIF1A), MAPK/ERK (Elk-1/SRF) and MAPK/JNK (AP-1) was used to study the monensin 
modulated signalling (SABiosciences, Frederick, MD). The assay was performed according 
to manufacturer’s instructions. In brief, inducible transcription factor responsive firefly 
luciferase reporters with constitutively expressing Renilla construct transcription factor 
reporters were plated onto 96-well plates with transfection reagent (siLentFect, Bio-Rad 
Laboratories), followed by addition of cells and incubation for 24 hours. A mixture of non-
inducible firefly luciferase reporter and constitutively expressing Renilla construct was used 
as the negative control. After 24 hours of transfection, monensin (100 nM) and control 
treatment were added onto the cells and plates were incubated for 18 hours. The Dual-
LuciferaseReporter (DLR™) Assay System (Promega) was utilized in quantitation of 
reporters and results according to the manufactorer’s instructions. The change in the activity 
of each signalling pathway was determined by comparing the normalized luciferase activity 
of the reporters in monensin or solvent exposed cells. 
2.4 Wound healing assay 
The effect of monensin (10 nM, 100 nM and 1 µM) on prostate cancer cell migration was 
studied using a scratch wound assay. PC-3 cells were plated on 96-well plates (Essen 
ImageLock, Essen Instruments, UK) and a wound was scratched with wound scratcher 
(Essen Instruments). Compounds and appropriate controls were added immediately after 
wound scratching and wound confluence was monitored with Incucyte Live-Cell Imaging 
System and software (Essen Instruments). Wound closure was calculated for every hour for 
24 hours by comparing the mean relative wound density of three biological replicates in 
each experiment.  
2.5 Cell viability assay 
Cell viability was determined with CellTiter-Glo (CTG) cell viability assay (Promega, 
Madison, WI) according to the manufacturer’s instructions. Briefly, 2,000 cells per well were 
plated in 35 μl of their respective growth media and left to attach overnight. Monensin 
(100 nM) was added to the cells and incubated for 12 or 24 hours. CTG reagent was added 
and the signals were quantified using Envision Multilabel Plate Reader (Perkin-Elmer, 
Massachusetts, MA). 
2.6 RNA extraction and quantitative real-time PCR  
VCaP cells were exposed to monensin for 6 hours, total RNA was extracted and quantitative 
real-time PCR was done as previously described (Ketola et al. 2010). TaqMan gene expression 
probes and primers from the Universal Probe Library (Roche Diagnostics, Espoo, Finland) 
were used to study E-cadherin (5´-cccgggacaacgtttattac-3´ and 5´-gctggctcaagtcaaagtcc-3´) and 
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-actin (5´-ccaaccgcgagaagatga -3´ and 5´-ccagaggcgtacagggatag -3´) mRNA expression. Three 
replicate samples were studied. 
2.7 Fluorescence-Activated Cell Sorting analysis (FACS) 
VCaP and LNCaP cells were exposed to monensin (1 µM) for 6 hours, samples were fixed 
with 2% paraformaldehyde, and stained with CD44 (FITC-conjugated mouse monoclonal 
anti-human, BD Pharmingen™ 555478) and CD24 (PE-conjugated rat monoclonal anti-
human, Abcam ab25281) antibodies for 45 minutes at 4°C in the dark. Cells were washed 
and the fluorescence intensity was measured using Accuri C6 Flow Cytometer. 
2.8 Immuofluorescence staining  
For immunofluorescence stainings, VCaP cells were grown on cover slip slides and exposed 
to monensin for 6 hours. Cells were fixed with 4 % paraformaldehyde in PBS, permeabilized 
with 0.2% Triton X-100 in PBS for 15 min, and blocked with 2 % BSA/PBS for 30 min. Cells 
were stained with E-cadherin antibody (1:100 dilution, polyclonal rabbit anti-human, Cell 
Signaling Technology, MA, USA) and Alexa-conjugated polyclonal donkey anti-rabbit 
antibody was used for secondary staining (1:300 dilution, Invitrogen, Molecular Probes, 
Carlsbad, CA). Cell nuclei were stained with DAPI present in Vectashield mounting 
medium (Vector Labs) and images were taken with Zeiss Axiovert 200M Microscope with 
the spinning disc confocal unit Yokogawa CSU22 and a Zeiss Plan-Neofluar 63× oil/1.4 NA 
objective. Z-stacks with 1 airy unit optical slices were acquired with a step size of 0.5 μm 
between slices, and the maximum intensity projections were created with SlideBook 4.2.0.7 
software (Intelligent Imaging Innovations Inc., CO, USA). 
2.9 Statistical analyses 
Stars in the figures indicate the significance of the experiments calculated using Student’s t-
test (*P<0.05, **P<0.01, *** P<0.001). 
2.10 Steroid quantification 
VCaP cells (1x107 cells) were exposed to 1 µM monensin for 6 hours, harvested and counted. 
An internal standard (labeled C16:0) and chloroform:methanol  (2:5) mixture were added, 
the samples were homogenized with Retsch system (5 min, 20 Hz), centrifuged and the 
supernatants were collected and evaporated. MOX (25 µl, TS-45950, Thermo Scientific, 
Helsinki, Finland) was added and the mixture was incubated at 45°C for 60 minutes. Next, 
100 µl of MSTFA with 1% trimethylchlorosilane (Fluka, St. Louis, MO) was added and the 
mixture was incubated at 70°C for 60 minutes. Injection standard was added to the mixture 
before gas chromatography-mass spectrometry analysis (GC-MS, Agilent 6890 gas 
chromatograph (GC) combined with Agilent 5973 mass selective detector (MSD)). The 
injector (injection volume 1 µl with pulsed splitless injection) and MSD temperatures were 
230°C (MS Source) and 150°C (MS Quad). The analyses were performed on Supelco 38499-
02C capillary column. Selective ion monitoring using specific masses for each target analyte 
was used in the detection. The following steroids were quantified: 7-ketocholesterol, 
aldosterone, progesterone, pregnenolone, estrone, 17B-estradiol, 4B-hydroxycholesterol, 
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25-hydroxycholesterol, 5a,6a-epoxycholesterol (Mono-TMS), dihydrotestosterone and 
testosterone (the standards were from Steraloids, Newport, RI)).  
3. Results 
3.1 Monensin reduces NF-κB pathway activity in prostate cancer cells 
Here, we studied the effect of monensin exposure on the activities of ten cancer signalling 
pathways using Cancer pathway Reporter Array in prostate cancer cells. Inducible 
transcription factor responsive firefly luciferase reporters were transfected to VCaP and 
LNCaP cells with constitutively active Renilla reporters and incubated for 24 hours. 
Monensin (100 nM) or solvent control was added onto the transfected cells for 18 hours 
followed by measure of luciferase activities. The results are presented in Fig. 2. Comparison 
of the basal pathway activities in VCaP prostate cancer cells indicated that NF-κB was  
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Fig. 2. Cancer pathway activities in VCaP and LNCaP prostate cancer cells. A) VCaP and B) 
LNCaP cells were exposed to ethanol or 100 nM monensin for 24 hours and pathway 
activities were measured as described in the text. Results with negative control measuring 
the background firefly luciferase activity (non-inducible firefly luciferase reporter and 
constitutively expressing Renilla construct) are indicated and used to determine the basal 
pathway activities in VCaP and LNCaP cells. The y-axis was set to 50 to allow direct 
comparison of relative luciferase units (RLU) in VCaP and LNCaP cells, although the basal 
NK-κB activity in VCaP cells extended RLU 324. Statistical significance of monensin induced 
changes are shown for the active pathways *P<0.05, **P<0.01, ***P<0.001. 
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clearly the most active pathway (fold change FC > 300, compared to the negative control). In 
addition, TGF-ß (FC = 5), cell cycle (FC = 12), Myc/Max (FC = 7) and hypoxia (FC = 5) were 
active in VCaP cells. In LNCaP cells, MAPK/JNK was the most active pathway (FC = 30 
compared to the negative control), followed by NF-κB (FC = 23), p53 (FC = 10), Myc/Max 
(FC = 7) and hypoxia (FC = 6). Interestingly, NF-κB pathway was 14 times more active in 
TMPRSS2-ERG fusion positive VCaP cells than in ERG negative LNCaP cells. These results 
are in agreement with previous data indicating that ERG induces NF-κB activity in prostate 
cells in vitro and in vivo (Wang et al. 2010). The results with p53 pathway are also in 
accordance with the previous literature since VCaP cells are known to have an inactivating 
mutation in p53 (Trp-248) whereas LNCaP cells express the active form, supporting  further 
the overall functionality of the assay (van Bokhoven et al. 2003). 
Monensin exposure inhibited NF-κB activity in both VCaP (by 88%) and LNCaP (by 83%) 
cells. NF-κB is a transcription factor that regulates various cellular processes such as 
cellular antioxidant defence capacity (Gloire, Legrand-Poels & Piette 2006). These results 
suggest that monensin induced oxidative stress may result from reduced NF-κB 
signalling. In addition, monensin reduced TGF-ß (by 75%), cell cycle (by 85%) and 
Myc/Max (by 71%) activities in VCaP cells and p53 (by 94%), hypoxia (by 82%) and 
Myc/Max (by 90%) activities in LNCaP cells. The reduced Myc/Max signalling is 
supported by reduced MYC mRNA expression seen in monensin exposed VCaP and 
LNCaP cells (Ketola et al. 2010). Taken together, monensin reduced the activities of 
multiple signalling pathways such as NF-κB, TGF-ß, hypoxia and Myc/Max, all 
associated with cancer cell survival, oxidative stress, stem cell potential and metastasis 
(Jones, Pu & Kyprianou 2009, Blum et al. 2009, Mimeault, M. & Batra, S.K. 2011, Benassi et 
al. 2006, Koh et al. 2010).  
3.2 Monensin reduces the cancer stem cell population in prostate cancer cell cultures 
Monensin exposure reduced the activities of multiple pathways maintaining antioxidative 
capacity and promoting the growth and survival of cancer stem cells such as NF-κB, 
HIF1A, MYC and ALDH, in cultured prostate cancer cells. Therefore, the effect of 
monensin on prostate cancer stem cell population was studied. Prostate cancer stem cells 
can be identified by high expression of CD44 and low expression of CD24 antigens 
(Klarmann et al. 2009). Interestingly, CD44 cell surface glycoprotein has recently been 
shown to increase antioxidative capacity in cancer cells, indicating that cancer initiating 
cells could be targeted by impairing oxidative stress defence mechanisms (Ishimoto et al. 
2011). Thus, we analyzed the effect of monensin exposure to the fraction of CD44+/CD24- 
cells in cultured prostate cancer cells. VCaP and LNCaP cells exposed to monensin (1 µM) 
for 6 hours were stained with CD44 and CD24 recognizing antibodies and the samples 
were analyzed using FACS. The results showed that monensin reduced the fraction of 
CD44+/CD24- cells in both VCaP (from 3 to 1.3%) and LNCaP (3.1 to 2.6%) cells (Fig. 3). In 
agreement with these results, genome-wide gene expression analysis indicated that 
monensin decreased CD44 (by 20%) and induced CD24 (by 30%) mRNAs compared to the 
levels in ethanol control at 6-hour time point (Ketola et al. 2010). Taken together, these 
results indicate that monensin reduces the fraction of cancer stem cells in prostate cancer 
cell cultures. 
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Fig. 3. FACS analysis of CD44 and CD24 immunostained VCaP and LNCaP prostate cancer 
cells. Monensin reduces the fraction of CD44+/CD24- cells in cultured prostate cancer cells. 
VCaP and LNCaP cells were stained with CD44 and CD24 antibodies in response to six hour 
monensin or ethanol exposure. Representative images from one out of four replicates are 
shown. 
3.3 Monensin induces cell differentiation in prostate cancer cells 
Cancer stem cells have been hypothesized to arise intrinsically through oncogenic 
transformation of normal tissue stem or progenitor cells in the early stage of the 
tumorigenesis or through induction of epithelial-to-mesenchymal transition (EMT) at later 
stages (Chaffer, Weinberg 2011). The expression of E-cadherin is considered as a marker of 
epithelial differentiation and it is lost during EMT. Interestingly, ERG knock-down in VCaP 
cells has been shown to induce E-cadherin expression (Gupta et al. 2010). Moreover, our 
previous results indicated that monensin reduced ERG expression in VCaP cells (Ketola et 
al. 2010). Thus, to study whether monensin affects prostate cancer cell differentiation, 
E-cadherin expression was analysed in monensin exposed VCaP cells. The results from 
immunochemical staining and quantitative RT-PCR showed that monensin induced 
E-cadherin expression in VCaP cells (Fig. 4A and B), indicating that monensin promotes cell 
differentiation in cultured prostate cancer cells. 
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Fig. 4. Monensin induces E-cadherin expression in VCaP prostate cancer cells. A) 
Immunofluorescence staining of E-cadherin (red) in response to 1 µM monensin or ethanol 
(ctrl) for 6-hour in VCaP cells. Nuclei are stained with DAPI (blue). B) Relative mRNA 
expression of E-cadherin in response to 1 µM monensin or ethanol (ctrl) exposure for 6-hour 
in VCaP cells.  
3.4 Monensin reduces migration in cultured prostate cancer cells 
Epithelial-to-mesenchymal transition is a perquisite for cancer cell migration (Baum, 
Settleman & Quinlan 2008). Moreover, in addition to the role in promoting cancer stem cell 
growth and survival, NF-κB and ALDH activities as well as high CD44 and low CD24 
expressions are known to enhance prostate cancer cell migration (van den Hoogen et al. 
2010, Klarmann et al. 2009). Since monensin induced cell differentiation, the effect of 
monensin exposure on prostate cancer cell migration was studied. VCaP and LNCaP cells 
do not migrate and therefore PC-3 prostate cancer cells were used as a model in migration 
assay. The results are presented in Fig. 5. Interestingly, already at 10 nM concentration, 
monensin significantly reduced cell migration. The anti-migratorial effect was stronger at 
higher concentrations (100 nM and 1 µM) (Fig. 5A). Thus, monensin was able to reduce cell 
migration at nanomolar concentrations in PC-3 cells although the same concentrations did 
not significantly decrease cell viability in these cells even at 24 hour time point (Fig. 5B). 
Pictures showing the decrease in wound closure in monensin exposed PC-3 cells in 
comparison to control are shown at 12 and 24 hour time points in Fig. 5C.  
3.5 Monensin increases oxidative stress inducing steroids as well as reduces the 
level of androgen precursor and antioxidative steroid 
Our previous results indicated that monensin induced oxidative stress and altered the 
expression of genes involved in cholesterol and steroid biosynthesis (Ketola et al. 2010). 
Moreover, monensin reduced androgen receptor (AR) signalling and showed synergistic 
growth inhibitory effects with anti-androgens in prostate cancer cells. To validate the 
monensin induced changes in cellular steroid levels, steroid profiling was performed in 
VCaP prostate cancer cells. Cells were exposed to ethanol or monensin (1 µM) for six hours 
and steroid profiles were studied using gas chromatocraphy - mass spectrometry (GC-MS). 
The results presented as a heat-map in Fig. 6 show that the most prominent changes in 
response to monensin exposure were the induction of 7-ketocholesterol and aldosterone  
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Fig. 5. The effect of monensin exposure on PC-3 prostate cancer cell migration. A) Relative 
wound confluency in response to monensin (10 nM, 100 nM and 1 µM) or control (ethanol) 
was monitored for 24 hours. B) Results from cell viability assay in response to monensin 
exposure (100 nM) for 12 and 24 hours in PC-3 cells. C) Pictures of scratch-wounded wells in 
response to 100 nM monensin or ethanol exposure at 12- and 24-hour time points. The 
wound margin in the beginning of the experiment is coloured in dark grey. 
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Fig. 6. Steroid profiling heat-map of monensin exposed VCaP prostate cancer cells. The cells 
were exposed to monensin (1 µM) for 6 hours and the steroid profile was measured with gas 
chromatography-mass spectrometry (GC-MS). The levels of individual steroids in monensin 
exposed cells were compared to ethanol exposed samples (presented as fold change, red: 
induction, blue: reduction).  
www.intechopen.com
 
Monensin Induced Oxidative Stress Reduces  
Prostate Cancer Cell Migration and Cancer Stem Cell Population 
 
531 
levels as well as decrease in progesterone and pregnenolone levels. Aldosterone and 7-
ketocholesterol are known oxidative stress inducers whereas progesterone has antioxidant 
properties (Leonarduzzi et al., 2006, Gramajo et al., 2010, Lee et al., 2009, Calo et al., 2010, 
Queisser et al., 2011, Ozacmak et al., 2009). Moreover, progesterone and pregnenolone are 
androgen precursors which have been suggested to play a major role in prostate cancer cell 
survival (Locke et al. 2008). Interestingly, progesterone has also been shown to promote 
mammary stem cell expansion (Joshi et al. 2010). The steroid profiling validates also the 
previous Connectivity Map results which indicated that monensin has opposite effects to 
progesterone and pregnenolone (Ketola et al. 2010). Taken together, monensin induced 
alterations in cellular steroid profile indicated that monensin induced oxidative stress 
results from increased aldosterone and 7-ketocholesterol levels as well as decreased 
progesterone and pregnenolone levels.  
4. Conclusion 
In this study, we explored the molecular consequences of monensin exposure in cultured 
prostate cancer cells. Our previous study indicated that monensin inhibited selectively 
prostate cancer cell viability at nanomolar concentrations by inducing oxidative stress. 
Cancer cells are constantly under pro-oxidative state (Szatrowski, Nathan 1991, Toyokuni et 
al. 1995). Long-term oxidative stress stimulates cell growth and proliferation, contributes to 
metastatic process and promotes cancer cell invasiveness and migration (Mori, Shibanuma 
& Nose 2004, Sung et al. 2006). Therefore, cancer cells need strong antioxidant mechanisms 
to survive and profit from these oxidative stress induced changes. Interfering redox balance 
has been suggested as a potential mean to selectively target cancer cells for example by 
increasing the cellular ROS level or reducing the expression of antioxidative enzymes 
(Pelicano, Carney & Huang 2004). Our results with monensin support this hypothesis. 
Our previous Connectivity Map results indicated that monensin has agonistic effects to 
NF-κB inactivator and oxidative stress inducer niclosamide supporting monensin as a 
potent NF-κB inhibitor. Here, we showed that although monensin reduced the activities of 
several pathways known to play a role in tumourigenesis, the strongest reduction was seen 
in NF κB signalling. NF-κB activity promotes cell viability, tumorigenesis and metastasis as 
well as correlates with poor prognosis in prostate cancer patients (Blum et al. 2009, Sarkar et 
al. 2008). Importantly, NF-κB regulates the expression of genes responsible for antioxidant 
defence capacity and its inhibition induces oxidative stress as well as reduces 
tumourigenesis, metastasis and cancer stem cell potential (Gloire, Legrand-Poels & Piette 
2006, Sarkar et al. 2008, Gluschnaider et al. 2010). NF-κB inhibitors are known to decrease 
AR signalling in vitro and reduce the growth of androgen deprivation-resistant prostate 
cancer xenografts in vivo (Jin et al. 2008, Zhang et al. 2009b). However, at present no specific 
NF-κB inhibitors have reached the stage of clinical trials for prostate cancer treatment 
(Mahon et al. 2011). Our results support NF-κB as the main mediator of monensin induced 
oxidative stress, which may also contribute to the reduced androgen signalling and 
induction of apoptosis in monensin exposed prostate cancer cells.  
Recently, cancer stem cell targeting has raised a lot of interest as a prominent way to target 
cancer drug resistance and metastasic growth (Mimeault, Batra 2011, Clayton, Mousa 2011). 
In comparison to cancer cells, ROS levels in cancer stem cells are lower due to controlled 
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redox balance system such as high ALDH and CD44 expression protecting cancer stem cells 
from oxidative stress (Kobayashi, Suda 2011a, Croker, Allan 2011, Ishimoto et al. 2011). 
Interestingly, NF-κB inhibition induces apoptosis in prostate cancer stem cells and thus 
NF-κB is considered as an attractive chemotherapeutic target also against cancer stem cells 
(Jin et al. 2008, Birnie et al. 2008). Since monensin reduced ALDH and NF-κB activities, we 
studied the fraction of CD44+/CD24- cells in prostate cancer cell cultures in response to 
monensin exposure. The results confirmed that monensin reduced the amount of prostate 
cancer stem cells. Moreover, monensin induced epithelial cell differentiation and reduced 
motility in cultured prostate cancer cells, suggesting that monensin inhibits prostate 
tumorigenesis by multiple ways. Cancer stem cell inhibitor and cell differentiation inducer 
salinomycin shares a similar structure as monensin, supporting the functional similarities 
between these two compounds (Gupta et al. 2009).  
Steroidogenic enzymes as well as stem cell markers are induced in castration-resistant 
prostate cancer both in vitro and in vivo (Blum et al. 2009, Pfeiffer et al. 2011). Several 
studies have shown that steroidogenesis is inhibited by ROS (Tsai et al. 2003, Stocco, 
Wells & Clark 1993, Kodaman, Aten & Behrman 1994, Lee et al. 2009, Abidi et al. 2008). 
Our previous results indicated that monensin reduced androgen receptor signalling. Here, 
we showed that monensin increases the levels of oxidative stress inducing steroids, 7-
ketocholesterol and aldosterone, and reduces androgen precursor and antioxidative steroid 
progesterone in cultured prostate cancer cells. Interestingly, 7-ketocholesterol is a ligand 
for aryl hydrocarbon receptor (AhR) and acts as AhR antagonist (Savouret et al. 2001). 
AhR expression is elevated in malignant prostate cells and its signalling is activated in 
prostate cancer stem cells (Blum et al. 2009, Gluschnaider et al. 2010). AhR pathway 
increases the expression of ALDH proteins and protects cells against oxidative stress and 
foreign chemicals (Lindros et al. 1998, Vrzal, Ulrichova & Dvorak 2004, Nebert et al. 2000, 
Kohle, Bock 2007). Interestingly, AhR binds to NF-κB, induces MYC activation and 
reduces E-cadherin expression in breast cancer cells (Kim et al. 2000, Dietrich, Kaina 2010). 
Moreover, AhR can form a complex with androgen receptor and protect prostate cancer 
cells during androgen ablation (Ohtake, Fujii-Kuriyama & Kato 2009, Gluschnaider et al. 
2010). Thus, our results indicate that monensin induced oxidative stress is potentially 
transmitted via reduced AhR signalling. This hypothesis is further supported by our 
previous gene expression results indicating that although AhR itself was not altered, the 
expression of AhR target gene mRNAs were decreased in response to monensin exposure 
(Ketola et al. 2010).  
Taken together, we hypothesize that monensin induced anti-neoplastic effects result mainly 
due to increase in oxidative stress. The overview figure 7 illustrates the various changes 
occurring in prostate cancer cells in response to monensin exposure. The cancer 
selectiveness could be explained by increased intracellular ROS due to reduced 
antioxidative capacity sensitizing prostate cancer cells to oxidative stress. Since normal 
prostate epithelial cells are not under intensive oxidative stress and therefore, are less 
dependent on the function of antioxidative genes, they are not as sensitive to monensin 
exposure as cancer cells. In conclusion, our results support the idea that impairing the redox 
control, which has a crucial role in cancer cells enabling survival in high intracellular ROS, is 
a potent way to target prostate cancer cells.  
www.intechopen.com
 
Monensin Induced Oxidative Stress Reduces  
Prostate Cancer Cell Migration and Cancer Stem Cell Population 
 
533 
R
O
S
prostate cancer cell
7-ketocholesterol
aldosterone
progesterone
pregnenolone
Antioxidative capacity
ALDH
NF-kB
AhR
Pro-oxidants
AR signalling, MYC, ERG
ROS
CD44+/CD24-
R
O
S
 
Fig. 7. Overview of monensin induced changes in prostate cancer cells. The figure idea 
adapted from Cairns, R.A., Harris, I.S. & Mak, T.W. 2011. 
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